## 轻松健康剥离“轻松筹”后陷入流量真空与盈利困境
On December 23, 2025 Qingsong Health Group listed on the Hong Kong Stock Exchange, opening 120% above its issuance price and briefly surpassing HK$11.4 billion in market value. The internet healthcare company, founded more than a decade ago, seemed to have reached a capital milestone—yet only months earlier it was still mired in an aborted IPO and a cliff-like drop in users. From Qingsongchou to Qingsong Health, from a public-interest crowdfunding platform to an AI healthcare concept stock, the company’s ten-year path highlights the difficult tug-of-war between its charitable origins and commercial monetization. A recent complaint from Sichuan college students accusing the platform of using donor data for insurance marketing has pushed this dispute back into the spotlight; the user-drain issue remains unresolved and trust is eroding further. Although Qingsong Health paints a bright outlook and the capital markets seem optimistic, performance data and actual user experiences tell a different story. Founded in 2014, Qingsong Health's founder Yang Yin entered the internet philanthropy space by focusing on critical illness aid. The platform quickly gained traction with its zero fees and fast fundraising model, accumulating millions of users within a year. In 2016, it launched the insurance arm Qingsong Insurance, creating a business model that relied on charity campaigns to drive insurance sales. By 2019, Qingsong Insurance's premium income exceeded RMB 5 billion, accounting for 78% of the group's total revenue. However, under the Special Administrative Measures on Foreign Investment Access, personal assistance services fall under restricted foreign investment, and Qingsong Health's Cayman Islands registration classifies it as a foreign-funded company—making its core traffic channel, Qingsongchou, a compliance obstacle for listing. In June 2024 the group made a disfiguring decision: it spun off Qingsongchou and the Dore Hospital business from the listing entity. The move cleared compliance hurdles, allowing the company to obtain overseas listing registration from the China Securities Regulatory Commission in October 2025 and successfully go public in Hong Kong two months later. Yet the cost was steep: active platform users plunged from over 70 million in 2022 to just over 20 million in 2025, a loss of nearly 50 million people. Average dwell time fell from several minutes to roughly 30 seconds, and without the crowdfunding business the platform lost the emotional scenarios that fostered deep user engagement. Despite the shares doubling since listing, Qingsong Health now battles a traffic vacuum and profit deterioration after divesting Qingsongchou. To fill the gap, sales and marketing expenses surged 153% year over year in the first three quarters of 2024, yet gross margin plunged from 82.6% in 2022 to 32.5% in the same period. RandD investment has also declined, dropping from 13.4% of revenue in 2022 to 5.4% in the first half of 2025. The company is trying to craft a new narrative around AI plus health services, but the story lacks a solid foundation amid weakened RandD and intense competition among AI healthcare giants. When a platform that rose on Qingsongchou must shed its crowdfunding arm to go public, and a charity-rooted service repeatedly draws complaints over insurance marketing, short-lived traffic booms are not enough—compliance is the floor, but value creation is the real foundation.
---
- **Source**: 
- **Sector**: The Vault
- **Tags**: 互联网医疗, ipo, 众筹, 保险, 用户流失
- **Credibility**: unverified
- **Published**: 2026-03-03 09:21:42
- **ID**: 1645
- **URL**: https://whisperx.ai/en/intel/1645